EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer

Shao-Ying Yang, Ming-Liang Jin, Lisa Andriani, Qian Zhao, Yun-Xiao Ling, Cai-Jin Lin, Min-Ying Huang, Jia-Yang Cai, Yin-Ling Zhang, Xin Hu, Zhi-Ming Shao, Fang-Lin Zhang und 3 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci183531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Shao-Ying Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Drug Resistance, Neoplasm, Kinesins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone receptor–positive and human epidermal growth factor receptor 2–negative breast cancer (HR + /HER2 − BC) is the most common subtype, with a high risk of long-term recurrence and metastasis. Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is a standard treatment for advanced/metastatic HR + /HER2 – BC, but resistance remains a major clinical challenge. We report that kinesin family member C2 ( KIFC2 ) was amplified in approximately 50% of patients with HR + /HER2 – BC, and its high expression was associated with poor disease outcome, increased tumor protein p53 ( TP53 ) somatic mutation, and active pyrimidine metabolism. Functional assays revealed that depletion of KIFC2 suppressed growth and enhanced sensitivity of HR + /HER2 – BC cells to tamoxifen and CDK4/6 inhibitors. Mechanistically, KIFC2 stabilized CDK4 by enhancing its interaction with ubiquitin-specific peptidase 9 X-linked (USP9X). Importantly, reexpression of CDK4 in KIFC2-depleted cells partially rescued the decreased growth and increased sensitivity to tamoxifen and CDK4/6 inhibitors caused by KIFC2 depletion. Clinically, high KIFC2 mRNA expression was negatively associated with the survival rate of patients with HR + /HER2 – BC who received adjuvant ET alone or in combination with CDK4/6 inhibitors. Collectively, these findings identify an important role for KIFC2 in HR + /HER2 – BC growth and therapeutic resistance, and support its potential as a therapeutic target and predictive biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Drug Resistance, NeoplasmKinesinsErb-b2 Receptor Tyrosine KinasesNeoplasm ProteinsHumansFemaleCell Line, TumorMiceAnimals

Stichwörter der Autor:innen

Breast cancerCell biologyDrug therapyMolecular biologyOncologyTherapeutics

Substanzen

Cyclin-Dependent Kinase 4KinesinsErb-b2 Receptor Tyrosine KinasesNeoplasm ProteinsCDK4 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
  • Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Shanghai Key Laboratory of Breast Cancer, Shanghai Medical College, Fudan University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Natural Science Foundation

Zitieren

APA

Yang, S. Y., Jin, M. L., Andriani, L., Zhao, Q., Ling, Y. X., Lin, C. J., Huang, M. Y., Cai, J. Y., Zhang, Y. L., Hu, X., Shao, Z. M., Zhang, F. L., Jin, X., Cao, A. Y., & Li, D. Q. (2025). Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci183531

Vancouver

Yang SY, Jin ML, Andriani L, Zhao Q, Ling YX, Lin CJ, et al. Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci183531

BibTeX
@article{Yang2025,
  author = {Yang, Shao-Ying and Jin, Ming-Liang and Andriani, Lisa and Zhao, Qian and Ling, Yun-Xiao and Lin, Cai-Jin and Huang, Min-Ying and Cai, Jia-Yang and Zhang, Yin-Ling and Hu, Xin and Shao, Zhi-Ming and Zhang, Fang-Lin and Jin, Xi and Cao, A Yong and Li, Da-Qiang},
  title = {Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci183531}
}
Kostenlos starten →